Source link : https://www.newshealth.biz/health-news/fda-approves-neoadjuvant-adjuvant-durvalumab-for-nsclc/
The US Food and Drug Administration (FDA) has approved durvalumab (Imfinzi; AstraZeneca) both before and after surgery in patients with resectable non–small cell lung cancer (NSCLC) without EGFR mutations or ALK rearrangements. The agency approved durvalumab alongside platinum-containing chemotherapy in the neoadjuvant setting and as monotherapy in the adjuvant setting. The approval comes shortly after […]
Author : News Health
Publish date : 2024-08-16 14:19:37
Copyright for syndicated content belongs to the linked Source.
Categories